Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

146 results about "Epileptic disorder" patented technology

Epilepsy is a group of neurological disorders characterized by epileptic seizures. Epileptic seizures are episodes that can vary from brief and nearly undetectable periods to long periods of vigorous shaking.

Method, apparatus, and surgical technique for autonomic neuromodulation for the treatment of disease

InactiveUS20060167498A1Reduce or prevent conditionReducing and preventing symptomSpinal electrodesSurgical needlesSplanchnic nervesDisease
The present invention teaches a method and apparatus for physiological modulation, including neural and gastrointestinal modulation, for the purposes of treating several disorders, including obesity, depression, epilepsy, and diabetes. This includes chronically implanted neural and neuromuscular modulators, used to modulate the afferent neurons of the sympathetic nervous system to induce satiety. Furthermore, this includes neuromuscular stimulation of the stomach to effect baseline and intermittent smooth muscle contraction to increase gastric intraluminal pressure, which induces satiety, and stimulate sympathetic afferent fibers, including those in the sympathetic trunk, splanchnic nerves, and greater curvature of the stomach, to augment the perception of satiety.
Owner:DILORENZO BIOMEDICAL

Methods and systems for recommending an appropriate pharmacological treatment to a patient for managing epilepsy and other neurological disorders

The present invention provides systems and methods for managing epilepsy. In one embodiment, a method of the present invention characterize a patient's propensity for a future epileptic seizure and communicates to the patient and / or a health care provider a therapy recommendation. The therapy recommendation is typically a function of the patient's propensity for the future epileptic seizure.
Owner:CYBERONICS INC

Vagal nerve stimulation techniques for treatment of epileptic seizures

The present invention uses electrical stimulation of the vagus nerve to treat epilepsy with minimized or no effect on the heart. Treatment is carried out by an implantable signal generator, one or more implantable electrodes for electrically stimulating a predetermined stimulation site of the vagus nerve, and a sensor for sensing characteristics of the heart such as heart rate. The heart rate information from the sensor can be used to determine whether the vagus nerve stimulation is adversely affecting the heart. Once threshold parameters are met, the vagus nerve stimulation may be stopped or adjusted. In an alternative embodiment, the invention may include a modified pacemaker to maintain the heart in desired conditions during the vagus nerve stimulation. In yet another embodiment, the invention may be simply a modified pacemaker having circuitry that determines whether a vagus nerve is being stimulated. In the event that the vagus nerve is being stimulated, the modified pacemaker may control the heart to maintain it within desired conditions during the vagus nerve stimulation.
Owner:OSORIO IVAN +1

Modulation and analysis of cerebral perfusion in epilepsy and other neurological disorders

A system including an implantable neurostimulator device capable of modulating cerebral blood flow to treat epilepsy and other neurological disorders. In one embodiment, the system is capable of modulating cerebral blood flow (also referred to as cerebral perfusion) in response to measurements and other observed conditions. Perfusion may be increased or decreased by systems and methods according to the invention as clinically required.
Owner:NEUROPACE

Methods and devices for the treatment of neurological and physiological disorders

Novel devices and methods that affect the neurologic and biological electrical conduction systems for the treatment various neurological and physiological disorders. Localized mechanical forces imparted by the inventive devices and methods modify or alter the mechanoelectric and or electrochemical properties of the affected tissues and biologic systems. Combinations of various technologies can be incorporated into the devices and methodologies for specific treatments. The devices and methods can be used to treat a number of neurologic and physiologic disorders such as Parkinson's, epilepsy, atrial fibrillation, cardiac arrhythmia, obesity, and others.
Owner:MISCHE HANS A

Skull-mounted electrical stimulation system and method for treating patients

A system and method for applying electrical stimulation or drug infusion to nervous tissue of a patient to treat epilepsy, movement disorders, and other indications uses at least one implantable system control unit (SCU) (110), including an implantable signal / pulse generator (IPG) and one or more electrodes (152, 152′). The IPG is implanted in the mastoid area (143) of the skull (140) and communicates with at least one external appliance (230), such as a Behind-the-Ear (BTE) unit (100). In a preferred embodiment, the system is capable of open- and closed-loop operation. In closed-loop operation, at least one SCU includes a sensor, and the sensed condition is used to adjust stimulation parameters.
Owner:BOSTON SCI NEUROMODULATION CORP

Nanocell drug delivery system

Nanocells allow the sequential delivery of two different therapeutic agents with different modes of action or different pharmacokinetics. A nanocell is formed by encapsulating a nanocore with a first agent inside a lipid vesicle containing a second agent. The agent in the outer lipid compartment is released first and may exert its effect before the agent in the nanocore is released. The nanocell delivery system may be formulated in pharmaceutical composition for delivery to patients suffering from diseases such as cancer, inflammatory diseases such as asthma, autoimmune diseases such as rheumatoid arthritis, infectious diseases, and neurological diseases such as epilepsy. In treating cancer, a traditional antineoplastic agent is contained in the outer lipid vesicle of the nanocell, and an antiangiogenic agent is loaded into the nanocore. This arrangement allows the antineoplastic agent to be released first and delivered to the tumor before the tumor's blood supply is cut off by the antianiogenic agent.
Owner:MASSACHUSETTS INST OF TECH

Selective neurostimulation for treating epilepsy

A method and device for treating epilepsy are disclosed which provide for electrical, chemical or magnetic stimulation of certain areas of the brain to modulate neuronal activity of areas associated with symptoms of epilepsy. Deep brain stimulation is combined with vagus nerve stimulation to enhance symptomatic relief of the disorder. Some embodiments also employ a sensing capability to optimize the therapeutic treatment regimen.
Owner:LIVANOVA USA INC

Methods and systems for administering an appropriate pharmacological treatment to a patient for managing epilepsy and other neurological disorders

The present invention provides systems and methods for managing epilepsy. In one embodiment, a method of the present invention characterize a patient's propensity for a future epileptic seizure and facilitates administration of a pharmacological agent. The dosage of the pharmacological agent is typically a function of at least one of the patient's propensity for the future epileptic seizure and time period to seizure.
Owner:CYBERONICS INC

Fluorinated lysine derivatives as dipeptidyl peptidase IV inhibitors

The invention relates to new therapeutically active and selective inhibitors of the enzyme dipeptidyl peptidase-IV (“DPP-IV”), pharmaceutical compositions comprising the compounds and the use of such compounds for treating diseases that are associated with proteins that are subject to processing by DPP-IV, such as Type 2 diabetes, metabolic syndrome (syndrome X or insulin resistance syndrome), hyperglycemia, impaired glucose tolerance, glucosuria, metabolic acidosis, arthritis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, conditions exacerbated by obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, short bowel syndrome, anxiety, depression, insomnia, chronic fatigue, epilepsy, eating disorders, chronic pain, alcohol addiction, diseases associated with intestinal motility, ulcers, irritable bowel syndrome, inflammatory bowel syndrome and to prevent disease progression in Type 2 diabetes. The invention also relates to a method of identifying an insulin secretagogue agent for diabetes.
Owner:PFIZER INC

Method and system to provide therapy or alleviate symptoms of involuntary movement disorders by providing complex and/or rectangular electrical pulses to vagus nerve(s)

A method and system for providing rectangular and / or complex electrical pulses for neuromodulating vagus nerve(s) and / or its branches, to provide therapy for involuntary movement disorders (including Parkinson's disease and epilepsy), comprises implantable and external components. Complex electrical pulses comprises pulses which are configured to be one of non-rectangular, multi-level, biphasic, or pulses with varying amplitude during the pulse. The electrical pulses to vagus nerve(s) may be stimulating and / or blocking. The stimulation and / or blocking to vagus nerve(s) may be provided using one of the following pulse generation means: a) an implanted stimulus-receiver with an external stimulator; b) an implanted stimulus-receiver comprising a high value capacitor for storing charge, used in conjunction with an external stimulator; c) a programmer-less implantable pulse generator (IPG) which is operable with a magnet; d) a microstimulator; e) a programmable implantable pulse generator; f) a combination implantable device comprising both a stimulus-receiver and a programmable implantable pulse generator (IPG); and g) an implantable pulse generator (IPG) comprising a rechargeable battery. The pulse generator means comprises predetermined / pre-packaged programs. In one embodiment, the pulse generation means may also comprise telemetry means, for remote interrogation and / or programming of said pulse generation means utilizing a wide area network.
Owner:BOVEJA BIRINDER R +1

Movement disorder stimulation with neural block

A method and apparatus for treating patients suffering from involuntary movement disorders (including epilepsy) by stimulating a selected cranial nerve of the patient with an electrical signal applied to induce a signal at brain by applying an electrical signal at the nerve to ameliorate the disorder and by applying a neural conduction block at the nerve selected to at least partially block nerve impulses on said nerve at a blocking site and reduce adverse effects of said signal on an organ.
Owner:RESHAPE LIFESCIENCES INC

Method, apparatus, surgical technique, and stimulation parameters for autonomic neuromodulation for the treatment of obesity

InactiveUS20070162085A1Reduce or prevent conditionReducing and preventing symptomSpinal electrodesHead electrodesSplanchnic nervesAfferent Neurons
The present invention teaches a method and apparatus for physiological modulation, including neural and gastrointestinal modulation, for the purposes of treating several disorders, including obesity, depression, epilepsy, and diabetes. This includes chronically implanted neural and neuromuscular modulators, used to modulate the afferent neurons of the sympathetic nervous system to induce satiety. Furthermore, this includes neuromuscular stimulation of the stomach to effect baseline and intermittent smooth muscle contraction to increase gastric intraluminal pressure, which induces satiety, and stimulate sympathetic afferent fibers, including those in the sympathetic trunk, splanchnic nerves, and greater curvature of the stomach, to augment the perception of satiety.
Owner:DILORENZO BIOMEDICAL

4-Aminoquinoline compounds

The present invention is concerned with compounds of the general Formula I: and pharmaceutically acceptable salts thereof, which are useful as melanin concentrating hormone receptor antagonists, particularly MCH-1R antagonists. As such, compounds of the present invention are useful for the treatment or prevention of obesity or eating disorders associated with excessive food intake and complications thereof, osteoarthritis, certain cancers, AIDS wasting, cachexia, frailty (particularly in elderly), mental disorders stress, cognitive disorders, sexual function, reproductive function, kidney function, locomotor disorders, attention deficit disorder (ADD), substance abuse disorders and dyskinesias, Huntington's disease, epilepsy, memory function, and spinal muscular atrophy. Compounds of formula I may therefore be used in the treatment of these conditions, and in the manufacture of a medicament useful in treating these conditions. Pharmaceutical formulations comprising one of the compounds of formula (I) as an active ingredient are disclosed, as are processes for preparing these compounds.
Owner:DEVITA ROBERT J +5

Treatment of mitochondrial diseases

InactiveUS20050065099A1Limit prevent damageBiocideSenses disorderHuntingtons choreaCerebellar ataxia
The invention relates the method of treatment or amelioration of mitochondrial disorders such as Alzheimer's disease, Parkinson's disease, Friedreich's ataxia (FRDA), cerebellar ataxias, Leber's hereditary optic neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), Myoclonic Epilepsy with Ragged Red Fibers (MERFF), amyotrophic lateral sclerosis (ALS), motor neuron diseases, Huntington's disease, macular degeneration, and epilepsy, with chroman derivatives of Formula I or Formula II as described herein.
Owner:EDISON PHARMA

Pro-neurogenic compounds

This technology relates generally to compounds and methods for stimulating neurogenesis (e.g., post-natal neurogenesis, including post-natal hippocampal and hypothalamic neurogenesis) and / or protecting neuronal cell from cell death. Various compounds are disclosed herein. In vivo activity tests suggest that these compounds may have therapeutic benefits in neuropsychiatric and / or neurodegenerative diseases such as schizophrenia, major depression, bipolar disorder, normal aging, epilepsy, traumatic brain injury, post-traumatic stress disorder, Parkinson's disease, Alzheimer's disease, Down syndrome, spinocerebellar ataxia, amyotrophic lateral sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of a neuro-active drug, retinal degeneration, spinal cord injury, peripheral nerve injury, physiological weight loss associated with various conditions, as well as cognitive decline associated with normal aging, chemotherapy, and the like.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST

Method of reducing injury to mammalian cells

This invention relates to methods of reducing the damaging effect of an injury to mammalian cells by treatment with compounds which reduce cell death or dysfunction, including cellular damage following episodes of tissue ischemia, trauma, epilepsy, and acute or chronic degeneration. The invention discloses methods of treating these disorders by administering inhibitors that disrupt protein-protein interactions involved in these disorders, screening methods to identify such inhibitors and specific compositions useful for treating these disorders.
Owner:NONO INC

Implantable Medical Device for Providing Chronic Condition Therapy and Acute Condition Therapy Using Vagus Nerve Stimulation

Disclosed herein are methods, systems, and apparatus for treating a medical condition in a patient using an implantable medical device (IMD). The IMD is capable of generating a first electrical signal for treating a medical condition, for example epilepsy. The first electrical signal relates to a long term therapy during a first time period in which there is no indication that the patient's brain is in an stable state, the first electrical signal being a microburst stimulation signal. The implantable device is also capable of generating a second electrical signal for treating the medical condition. The second electrical signal relates to a short term therapy during a second time period, in response to an indication that the patient's brain is in an unstable state. The second electrical signal in one example, may be a conventional stimulation signal.
Owner:LIVANOVA USA INC

Substituted aryl amides

Novel compounds of structural formula (I) are antagonists and / or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as psychotropic drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as, the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.
Owner:MERCK & CO INC

2-Aminoquinoline compounds

The present invention is concerned with compounds of the general Formula I: and pharmaceutically acceptable salts thereof, which are useful as melanin concentrating hormone receptor antagonists, particularly MCH-1R antagonists. As such, compounds of the present invention are useful for the treatment or prevention of obesity or eating disorders associated with excessive food intake and complications thereof, osteoarthritis, certain cancers, AIDS wasting, cachexia, frailty (particularly in elderly), mental disorders stress, cognitive disorders, sexual function, reproductive function, kidney function, locomotor disorders, attention deficit disorder (ADD), substance abuse disorders and dyskinesias, Huntington's disease, epilepsy, memory function, and spinal muscular atrophy. Compounds of formula I may therefore be used in the treatment of these conditions, and in the manufacture of a medicament useful in treating these conditions. Pharmaceutical formulations comprising one of the compounds of formula (I) as an active ingredient are disclosed, as are processes for preparing these compounds.
Owner:MERCK SHARP & DOHME CORP

Noninvasive nonlinear systems and methods for predicting seizure

The present invention relates to methods and devices for noninvasive nonlinear prediction of ictal onset in patients afflicted by neurological disease. In particular, the present invention provides methods and devices for noninvasive nonlinear prediction of seizures in patients afflicted with epilepsy. The devices and methods preferably being based on analysis of two or more electroencephalogram (EEG) recordings, one set of recordings taken from an electrode close to the region of ictal onset, and a second or more set of recordings (e.g., concurrent readings) taken from a region remote from the region of ictal onset.
Owner:RGT UNIV OF MICHIGAN

Systems and methods of classification utilizing intensity and spatial data

A method of classifying a test subject comprises collecting imaging data for a plurality of training subjects, control subjects and a test subject. An intensity volume of interest (VOI) and a spatial VOI are selected from said imaging data. Training intensity data and spatial data are calculated for the intensity and spatial VOI. A statistical model can then be created based on the training intensity data and training spatial data to provide a universe of subjects. Control intensity data and spatial data are also calculated for the intensity and spatial VOI. A classifier can then be built dividing the universe into at least two regions. The test subject data can then be applied to the classifier to provide a determination of whether said test subject falls within the first region or the second region. The condition can be a neurological disease state such as temporal lobe epilepsy or Alzheimer's dementia.
Owner:MCGILL UNIV

Modulation and analysis of cerebral perfusion in epilepsy and other neurological disorders

A system including an implantable neurostimulator device capable of modulating cerebral blood flow to treat epilepsy and other neurological disorders. In one embodiment, the system is capable of modulating cerebral blood flow (also referred to as cerebral perfusion) in response to measurements and other observed conditions. Perfusion may be increased or decreased by systems and methods according to the invention as clinically required.
Owner:NEUROPACE

O-desmethylvenlafaxine and methods of preparing and using the same

Methods of preparing, and compositions comprising, derivatives of venlafaxine are disclosed. Also disclosed are methods of treating and preventing diseases and disorders including, but not limited to, affective disorders such as depression, bipolar and manic disorders, attention deficit disorder, attention deficit disorder with hyperactivity, Parkinson's disease, epilepsy, cerebral function disorders, obesity and weight gain, incontinence, dementia and related disorders.
Owner:WYETH LLC

Non-invasive vagal nerve stimulation to treat disorders

Devices, systems and methods are disclosed for treating a variety of diseases and disorders that are primarily or at least partially driven by an imbalance in neurotransmitters in the brain, such as asthma, COPD, depression, anxiety, epilepsy, fibromyalgia, and the like. The invention involves the use of an energy source comprising magnetic and / or electrical energy that is transmitted non-invasively to, or in close proximity to, a selected nerve to temporarily stimulate, block and / or modulate the signals in the selected nerve such that neural pathways are activated to release inhibitory neurotransmitters in the patient's brain.
Owner:ELECTROCORE

Compounds and Methods for Treating Seizure Disorders

InactiveUS20060217303A1Reduce seizuresAlleviating paroxysmal disorderBiocideNervous disorderMedicineGluconeogenic enzymes
This invention provides methods for alleviating seizure disorders in an animal, particularly epilepsy, by regulating the flux through the gluconeogenic enzyme PEPCK in brain cells.
Owner:WISCONSIN ALUMNI RES FOUND
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products